What are the main products of UTHR?
United Therapeutics Corporation develops and commercializes innovative medical products and specialty therapeutics targeted at severe, life-threatening cardiovascular and pulmonary diseases, as well as organ-manufacturing technologies. Its primary commercial pharmaceutical portfolio features advanced treatments for pulmonary arterial hypertension, including Tyvaso delivered via inhalation systems, Orenitram, Remodulin, and Adempas. The enterprise also invests heavily in groundbreaking research initiatives focused on xenotransplantation, regenerative medicine, and bio-artificial organ development to address critical global shortages of transplantable human organs.
Related FAQs
Determining the price volatility of Victory Metals Limited—an exploration company focused on critical heavy rare earth elements and scandium mineral deposits—reveals an exceptionally high volatility profile typical of early-stage resource exploration...
Getting a job at The Coca-Cola Company varies widely in difficulty depending entirely on the specific department, functional role, and corporate tier you are targeting.
Determining whether United Therapeutics represents a worthwhile equity purchase involves analyzing its strong financial fundamentals, consistent profitability, and long-term growth catalysts in rare disease therapeutics and organ transplantation tech...
Companies that share a similar focus on biotechnology, rare diseases, and advanced cardiovascular therapeutics as United Therapeutics include specialized biopharmaceutical enterprises such as BioMarin Pharmaceutical, Alnylam Pharmaceuticals, United T...
Biotechnology analysts covering United Therapeutics Corporation (NASDAQ: UTHR) frequently issue favorable buy or hold recommendations, supported by strong commercial sales of its core pulmonary arterial hypertension therapies, robust research pipelin...
Uwharrie Bank provides comprehensive digital banking applications, online account management tools, and mobile check deposit features designed to help personal and commercial customers handle their daily financial transactions conveniently.
Biotechnology analysts covering United Therapeutics Corporation (NASDAQ: UTHR) generally issue favorable buy or hold recommendations, supported by robust commercial revenues from its core pulmonary arterial hypertension treatments and a pristine, deb...
Yes, Valero Energy Corporation (trading under the ticker VLO) has executed stock splits during its trading history as a premier independent petroleum refiner and marketer.
United Therapeutics Corporation operates as a major publicly traded biotechnology enterprise with multi-billion-dollar market capitalization and substantial annual revenue generation, though formal inclusion on the traditional Fortune 500 list fluctu...
United Therapeutics commercializes an innovative portfolio of advanced prescription medications targeted primarily at severe cardiovascular and pulmonary diseases, alongside organ manufacturing initiatives.
United Therapeutics Corporation (UTHR) equity research analysts maintain a favorable consensus Buy rating, with average 12-month price targets clustering around $663.23 to $681.38 per share, while high institutional estimates stretch up to $787.50.
Depending on the specific institution referenced, certain banking entities bearing the name have undergone brand evolutions or organizational name updates.
Identifying undervalued U.S. stocks requires continuous analysis of fundamental financial metrics such as price-to-earnings ratios, free cash flow generation, balance sheet strength, and intrinsic value estimations compared to current market prices.
United Therapeutics Corporation (UTHR) trades at market valuations reflecting strong commercial performance in biotechnology treatments for pulmonary hypertension.